替诺福韦酯联合拉米夫定治疗艾滋病合并乙型肝炎病毒感染的效果

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of Tenofovir Dipivoxil combined with Lamivudine in the treatment of AIDS combined with hepatitis B virus infection.Methods The 78 patients of AIDS with hepatitis B virus infection admitted to the 5th People′s Hospital of Ganzhou from September 2017 to January 2019 were selected as the research subjects.They were divided into a control group and an observation group according to the method of drawing lots,39 cases in each group.The control group was treated with Lamivudine,the observation group was treated with Tenofovir Dipivoxil combined with Lamivudine.The positive rate and content of hepatitis B virus (HBV) DNA,RNA conversion rate of human immunodeficiency virus (HIV),recurrence rate of alanine aminotransferase (ALT) and the total incidence of adverse reactions rate were compared between the two groups..Results After 6 months and 1 year of treatment,the positive rate and content of HBV DNA in the observation group were lower than those in the control group,the differences were statistically significant (P<0.05).After 6 months and 1 year of treatment,the HIV RNA negative rate and ALT normalization rate in the observation group were higher than those in the control group,the differences were statistically significant (P<0.05).There was no significant difference in total incidence of adverse reactions between the two groups (P>0.05).Conclusion Tenofovir Dipivoxil combined with Lamivudine in the treatment of AIDS complicated with hepatitis B virus infection has the advantages of high efficacy and safety,which is worthy of promotion.

Key words： Tenofovir Dipivoxil Lamivudine AIDS Hepatitis B Viral infection

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WU Jing
	AO Jian
	LIU Ping-qing
	HU Dian-gui

Cite this article:

WU Jing,AO Jian,LIU Ping-qing, et al. Effect of Tenofovir Dipivoxil combined with Lamivudine in the treatment of AIDS combined with hepatitis B virus infection[J]. 中国当代医药, 2020, 27(36): 49-51转59.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I36/49

[1]	黄卫娥.乙肝病毒对艾滋病病毒感染者外周血淋巴细胞、肝功能及血常规的影响[J].中国当代医药，2019，26（36）：37-39，43.
[2]	刘胜昔.替诺福韦与拉米夫定联合治疗艾滋病合并乙型肝炎病毒感染疗效观察[J].河北医药，2017，39（4）：589-591.
[3]	宋波译，王福祥.HIV 患者联合感染慢性乙肝和丙肝的临床处理和治疗指南[C].//中华医学会第四次全国艾滋病、病毒性丙型肝炎暨全国热带病学术会议论文汇编，2009：158-161.
[4]	兰青，范晶华，陈一晖，等.艾滋病合并乙型肝炎患者乙肝病毒血清学与HBV-DNA 的关系[J].昆明医科大学学报，2015，36（4）：152-156.
[5]	何宗运.替诺福韦酯联合拉米夫定治疗艾滋病合并乙型肝炎病毒感染的临床疗效及安全性研究[J].中华实验和临床感染病杂志（电子版），2015，9（2）：256-258.
[6]	陈清冉，李娟，陈琳，等.核苷类似物阻断慢性乙型肝炎病毒母婴传播的临床研究[J].中国妇幼保健，2018，33（24）：5719-5721.
[7]	黄思敏，蔡卫平，胡凤玉，等.艾滋病合并慢性乙型肝炎感染患者对拉米夫定耐药的研究[J].中华实验和临床病毒学杂志，2016，30（5）：473-476.
[8]	尹盛才.替诺福韦酯联合拉米夫定治疗艾滋病合并乙型肝炎病毒感染的临床效果分析[J].医学理论与实践，2017，30（20）：3045-3046.
[9]	樊正勤，曹灵芝，赵耘，等.核苷类似物干预后慢性乙型肝炎患者HBV 多聚酶区基因突变模式与危险因素分析[J].实用临床医药杂志，2017，21（5）：54-56.
[10]	周艳.替诺福韦酯联合拉米夫定治疗艾滋病合并乙型肝炎病毒感染的效果观察[J].河南医学研究，2016，25（4）：746-747.
[11]	夏华.替诺福韦酯联合拉米夫定治疗获得性免疫缺陷综合征合并乙型肝炎病毒感染的临床效果研究[J].中国医药，2018，13（5）：718-720.
[12]	吴明杰.替诺福韦酯联合拉米夫定、依非韦伦对艾滋病合并乙型肝炎病毒感染的治疗效果与安全性评价[J].中外医学研究，2019，17（2）：147-148.
[13]	李太生，李翊嘉，韩扬.替诺福韦、拉米夫定和利托那韦增强的洛匹那韦的二线治疗方案在经治HIV 感染患者中的疗效[J].中华内科杂志，2015，54（10）：885.
[14]	高化国.替诺福韦酯联合拉米夫定治疗艾滋病合并乙型肝炎病毒感染分析[J].系统医学，2016，1（8）：54-56.
[15]	张文霞，梁文霞.特殊艾滋病62例抗病毒治疗依从性影响因素临床分析[J].中国药物与临床，2016，16（6）：896-898.
[16]	张继红，张幼萍，洪航，等.宁波市HIV/AIDS 病人的抗病毒治疗依从性及影响因素[J].中国艾滋病性病，2017，23（5）：393-396.